BUZZ-Lisata jumps as Kuva Labs strikes acquisition deal

Reuters

Jan 21

** Shares of drug developer Lisata Therapeutics LSTA.O rise 85% to $3.99 premarket

** Co says it has agreed to be acquired by privately held Kuva Labs for $4 per share in cash, plus milestone payments of $2 per share tied to regaining China rights for its drug, certepetide, and a future approval filing

** Co's lead drug certepetide is being tested to help cancer drugs better penetrate solid tumors; Lisata expects key trial readouts over the next 18 months, co says

** Co says offer is an 85% premium to last close and could reach a 180% premium if both milestones are hit

** Deal unanimously approved; final agreement expected before Feb. 27 and subject to shareholder approval, co says

** Shares down ~38% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2605488103"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2605488103\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2605488103?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-21 22:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605488103","market":"nz","top_or_hot":-1,"title":"BUZZ-Lisata jumps as Kuva Labs strikes acquisition deal","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Lisata jumps as Kuva Labs strikes acquisition deal</title></head><body><p>** Shares of drug developer <a href=\"https://laohu8.com/S/LSTA\">Lisata Therapeutics</a> <span>LSTA.O</span> rise 85% to $3.99 premarket </p><p>** Co says it has agreed to be acquired by privately held Kuva Labs for $4 per share in cash, plus milestone payments of $2 per share tied to regaining China rights for its drug, certepetide, and a future approval filing</p><p>** Co's lead drug certepetide is being tested to help cancer drugs better penetrate solid tumors; Lisata expects key trial readouts over the next 18 months, co says</p><p>** Co says offer is an 85% premium to last close and could reach a 180% premium if both milestones are hit</p><p>** Deal unanimously approved; final agreement expected before Feb. 27 and subject to shareholder approval, co says</p><p>** Shares down ~38% in 2025</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Lisata jumps as Kuva Labs strikes acquisition deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Lisata jumps as Kuva Labs strikes acquisition deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-21 22:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Lisata jumps as Kuva Labs strikes acquisition deal</title></head><body><p>** Shares of drug developer <a href=\"https://laohu8.com/S/LSTA\">Lisata Therapeutics</a> <span>LSTA.O</span> rise 85% to $3.99 premarket </p><p>** Co says it has agreed to be acquired by privately held Kuva Labs for $4 per share in cash, plus milestone payments of $2 per share tied to regaining China rights for its drug, certepetide, and a future approval filing</p><p>** Co's lead drug certepetide is being tested to help cancer drugs better penetrate solid tumors; Lisata expects key trial readouts over the next 18 months, co says</p><p>** Co says offer is an 85% premium to last close and could reach a 180% premium if both milestones are hit</p><p>** Deal unanimously approved; final agreement expected before Feb. 27 and subject to shareholder approval, co says</p><p>** Shares down ~38% in 2025</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LSTA","symbol_name":"LISATA THERAPEUTICS INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL4N3YM1DQ:1","article_id":"2605488103","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605488103","pubTimestamp":1769005052,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Lisata jumps as Kuva Labs strikes acquisition deal** Shares of drug developer Lisata Therapeutics LSTA.O rise 85% to $3.99 premarket ** Co says it has agreed to be acquired by privately held Kuva Labs for $4 per share in cash, plus milestone payments of $2 per share tied to regaining China rights for its drug, certepetide, and a future approval filing** Co's lead drug certepetide is being tested to help cancer drugs better penetrate solid tumors; Lisata expects key trial readouts over the next 18 months, co says** Co says offer is an 85% premium to last close and could reach a 180% premium if both milestones are hit** Deal unanimously approved; final agreement expected before Feb. 27 and subject to shareholder approval, co says** Shares down ~38% in 2025","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LSTA":"LISATA THERAPEUTICS INC","BK4139":"生物科技"},"translate_title":"Kuva Labs达成收购协议，BUZZ-Lisata股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LSTA":0.9},"content_text":"BUZZ-Lisata jumps as Kuva Labs strikes acquisition deal** Shares of drug developer Lisata Therapeutics LSTA.O rise 85% to $3.99 premarket ** Co says it has agreed to be acquired by privately held Kuva Labs for $4 per share in cash, plus milestone payments of $2 per share tied to regaining China rights for its drug, certepetide, and a future approval filing** Co's lead drug certepetide is being tested to help cancer drugs better penetrate solid tumors; Lisata expects key trial readouts over the next 18 months, co says** Co says offer is an 85% premium to last close and could reach a 180% premium if both milestones are hit** Deal unanimously approved; final agreement expected before Feb. 27 and subject to shareholder approval, co says** Shares down ~38% in 2025(Reporting by Sahil Pandey in Bengaluru)((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}